Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1669927 | 0.93 | TSHR (0.50) | LTA4HNR5A1TSHR | |
| SCHEMBL10474244 | 0.93 | TSHR (0.50) | LTA4HNR5A1TSHR | |
| SCHEMBL160643 | 0.91 | KMT2A (0.41) | LTA4HCA12CA1CA2CA7 | |
| SCHEMBL27647098 | 0.87 | PDIA6 (0.34) | TSHRMEN1NPC1GAARAB9A | |
| SCHEMBL9935226 | 0.84 | NR1I2 (0.37) | TSHRALDH1A1GAA | |
| SCHEMBL9935566 | 0.84 | NOS3 (0.40) | TSHR | |
| SCHEMBL8345477 | 0.84 | MAOA (0.35) | TSHRNPC1MAPTRAB9A | |
| SCHEMBL15067951 | 0.83 | LTA4H (0.44) | LTA4HAHRNR5A1CA12CA1 | |
| SCHEMBL160560 | 0.82 | NQO1 (0.46) | LTA4HAHRCA12CA1CA7 | |
| SCHEMBL9935427 | 0.82 | NCF1 (0.44) | TSHRMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| US-8273770-B2 | 5-pyridinone substituted indazoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-09-25 | — | — | US | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| EP-2176251-B1 | 5-pyridinone substituted indazoles and pharmaceutical compositions thereof | ALBANY MOLECULAR RES INC (US) | 2012-02-08 | — | — | EP | claimed |
| US-20090082359-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | AMR TECHNOLOGY, INC. (US) | 2009-03-26 | — | — | US | claimed |
| US-6337423-B1 | BIND TO VOLTAGE-GATED SODIUM ION CHANNELS TO MODULATE ACTIVITY | ADVANCED MEDICINE, INC. | 2002-01-08 | — | — | US | claimed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | disclosed |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-10-29 | — | — | US | disclosed |
| EP-2176251-B1 | 5-pyridinone substituted indazoles and pharmaceutical compositions thereof | ALBANY MOLECULAR RES INC (US) | 2012-02-08 | — | — | EP | disclosed |
| CN-100564383-C | Organosilicon compound and manufacture method thereof | SUMITOMO CHEMICAL CO (JP) | 2009-12-02 | — | — | CN | disclosed |
| US-20090082359-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | AMR TECHNOLOGY, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| CN-1930174-A | Organosilicon compound and method for producing same | SUMITOMO CHEMICAL CO (JP) | 2007-03-14 | — | — | CN | disclosed |
| CN-1295558-A | Novel local anesthetic compounds and uses | ADVANCED MEDICINE INC (US) | 2001-05-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | LTA4H 2761/4885AHR 1940/4885NR5A1 1776/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | LTA4H 2984/4885AHR 1132/4885NR5A1 1196/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | LTA4H 2761/4885AHR 1940/4885NR5A1 1776/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | LTA4H 2984/4885AHR 1132/4885NR5A1 1196/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | LTA4H 2984/4885AHR 1132/4885NR5A1 1196/4885 |
| US-20090082359-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | CYP3A5, PNPO, NDUFS3 | LTA4H 2389/4885AHR 748/4885NR5A1 352/4885 |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | LTA4H 2984/4885AHR 1132/4885NR5A1 1196/4885 |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | LTA4H 2761/4885AHR 1940/4885NR5A1 1776/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | LTA4H 2761/4885AHR 1940/4885NR5A1 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.